BioCentury | May 6, 2020
Product Development

With time at a premium, Alnylam’s siRNA strategy against COVID-19 could give it an advantage

...a narrow Phase IIb miss of the primary endpoints. Two other companies, Sirnaomics Inc. and siRNAgen Therapeutics Corp....
Items per page:
1 - 1 of 1
BioCentury | May 6, 2020
Product Development

With time at a premium, Alnylam’s siRNA strategy against COVID-19 could give it an advantage

...a narrow Phase IIb miss of the primary endpoints. Two other companies, Sirnaomics Inc. and siRNAgen Therapeutics Corp....
Items per page:
1 - 1 of 1